Friday September 3, 2010
Pharma
AimsBio-Pharma
The discovery of novel antibiotics that control multidrug-resistant pathogens is the greatest challenge facing modern medicine. Our researchers are recovering natural product antibiotics from unique, unexplored sources and testing their effectiveness against the most devastating pathogens.
The core technology of AimsBio-Pharma is a new group of antibiotics termed Phyllobiotics. These novel compounds promise to elevate our fight against multidrug resistant pathogens so that we can overcome the most serious diseases.
The antibiotics market in the United States is $8.0 B and growing at roughly 8% per year. While novel antibiotics are a very strong market opportunity, the risk is whether promising candidates can make it through the maze of regulations required to reach their vast market potential. We feel this risk is worth every penny.
